Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRIUS-SLE extension long-term safety study of ianalumab in systemic lupus erythematosus
2023-505929-14-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Novartis. Primary endpoint: Incidence of treatment-emergent AEs (TEAEs)/SAEs. Planned start May 2024; status: authorised.
02
Drugs
ianalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-505929-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505929-14-00.